2020-03-18
Moderna, Inc., a USA-based biotechnology company specializing in messenger RNA therapeutics, announced that its much-awaited mRNA-based vaccine candidate (mRNA-1273) against the novel coronavirus disease (COVID-19) has just entered Phase 1 study, under the Investigational New Drug (IND) application of the National Institutes of Health (NIH). In this technology, the stretch of RNA which is...
